| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6109673 | Journal of Hepatology | 2009 | 8 Pages |
Abstract
VCH-759 was well tolerated and achieved a ⩾ 2 log10 decline in HCV RNA with 800 mg b.i.d. and t.i.d doses. In a subset of participants, viral rebound was observed and associated with resistant variants. This data supports further evaluation of VCH-759 in combination with interferon-ribavirin treatment.
Keywords
CC50CmaxSTAT-CRVRPiBtmaxSVRNon-nucleoside NS5B inhibitorIC90IC50t.i.d.ALT50% cytotoxic concentration50% inhibitory concentrationAUCDNALC/MS/MSt1/2ASTAspartate aminotransferaseAlanine aminotransferasedeoxyribonucleic acidribonucleic acidRNAstandard deviationsafety and tolerabilitymaximum concentrationPer-protocoltwice dailytime at maximum concentrationthree times dailybody mass indexBMItherapeutic indexadverse eventPharmacokineticspharmacokineticAntiviral activityArea-under-the-curveHalf-lifeHepatitis C virusHCVRapid virological responsesustained virological responseb.i.d.gastro-intestinal
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Curtis Cooper, Eric J. Lawitz, Peter Ghali, Maribel Rodriguez-Torres, Frank H. Anderson, Samuel S. Lee, Jean Bédard, Nathalie Chauret, Roch Thibert, Isabel Boivin, Olivier Nicolas, Louise Proulx,